Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Oncology (Williston Park) ; 32(11): 562-9, 2018 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-30474104

RESUMEN

Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor-positive breast cancer, but they are associated with bone loss and increased fracture risk. Although several guidelines for the management of osteoporosis and osteopenia exist, their algorithms do not account for the use of AIs. In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.


Asunto(s)
Antineoplásicos/efectos adversos , Inhibidores de la Aromatasa/efectos adversos , Conservadores de la Densidad Ósea/uso terapéutico , Remodelación Ósea/efectos de los fármacos , Neoplasias de la Mama/tratamiento farmacológico , Osteoporosis/prevención & control , Fracturas Osteoporóticas/prevención & control , Conservadores de la Densidad Ósea/efectos adversos , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Femenino , Humanos , Terapia Molecular Dirigida , Osteoporosis/inducido químicamente , Osteoporosis/diagnóstico , Osteoporosis/fisiopatología , Fracturas Osteoporóticas/inducido químicamente , Fracturas Osteoporóticas/diagnóstico , Fracturas Osteoporóticas/fisiopatología , Factores Protectores , Medición de Riesgo , Factores de Riesgo , Resultado del Tratamiento
2.
J Oncol Pract ; 10(2): e14-25, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24254406

RESUMEN

Chemotherapy is prone to medication error resulting from complexities in ordering and administration. Computerized physician order entry (CPOE) has been established as an important tool to minimize such errors and hence improve patient safety. As a leading Canadian advisory body in oncology, Cancer Care Ontario (CCO) has been a champion in developing and implementing its own cancer systemic therapy CPOE, the Oncology Patient Information System (OPIS). This article reviews and consolidates principles for oncology CPOE systems as found in the literature and in guidelines created by three international oncology organizations (American Society of Clinical Oncology, Clinical Oncological Society of Australia, and CCO). It then evaluates OPIS by these standards and provides a working example of what a cancer CPOE system should look like. This document can therefore be used as a framework to help develop and evaluate cancer CPOE platforms in different national settings. As end users, oncologists are considered key stakeholders in developing such systems and thus should be well informed about CPOE principles to help make decisions on the appropriate implementation of these platforms in their local practice settings. In addition, oncologists are also important champions for the successful uptake of oncology CPOE platforms and would benefit from a better understanding of whether proposed or existing local CPOE systems meet established standards.


Asunto(s)
Guías como Asunto , Oncología Médica/normas , Sistemas de Entrada de Órdenes Médicas , Neoplasias , Manejo de la Enfermedad , Humanos , Errores de Medicación/prevención & control , Neoplasias/tratamiento farmacológico , Ontario
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA